PTO/SB/08 (11-07)

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | Complete if Known | | |
|------------------------------|-----------------------------------|----------------------|-------------------|-------------------------|------------------|--|
| Substitute for form 1449/PTO | | | | Application Number | 10/537,756 | |
| INFORMATION DISCLOSURE | | | OSURE | Filing Date | October 25, 2005 | |
| STATEMENT BY APPLICANT | | First Named Inventor | David John Haydon | | | |
| (Use as | (Use as many sheets as necessary) | | Art Unit | 1652 | | |
| | (Use as many sneets as necessary) | | Examiner Name | Iqbal Hossain Chowdhury | | |
| Sheet 1 Of 4 | | | | Attorney Docket Number | 35813-709.831 | |

| | U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|--|--|
| Examiner Initials* | Cite No.1 | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | | |
| /IC/ | 11. | US-6,747,137 | 062004 | Weinstock et al. | | | |

| | | FOREIGN | PATENT DO | OCUMENTS | | |
|-----------------------|-------------|--|--------------------------------|--|---|----|
| Examiner Initials* | Cite No. | Foreign Patent Document Country Code ³ – Number ⁶ – Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | To |
| /IC/ | 12. | WO-2002-02784 | 01-10-2002 | Anadys Pharmaceuticals | | |
| /IC/ | 13. | WO-2001-60975 | 08-23-2001 | Boone et al. | | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|----|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T' |
| /IC/ | 14. | Aebi et al., "Isolation of a Temperature-sensitive Mutant with an Altered tRNA Nucleotidyltransferase and Cloning of the Gene Encoding tRNA Nucleotidyltransferase in the Yeast Saccharomyces cerevisiae," J. Biol. Chem. 265:16216–16220 (1990) | |
| /IC/ | 15. | Antifungal definition from Merriam-Webster Online Dictionary 11/08/06 | |
| /IC/ | 16. | Backen et al., "Evaluation of the CaMAL2 promoter for regulated expression of genes in Candida albicans," Yeast 16:1121-1129 (2000) | |
| /IC/ | 17. | Bruno et al., "Large-scale gene function analysis in Candida albicans," Trends Microbiol. 12:157-161 (2004) | |
| /IC/ | 18. | Chen et al., "Cytoplasmic and Mitochondrial tRNA Nucleotidyltransferase Activities Are Derived from the Same Gene in the Yeast Saccharomyces cerevisiae," J. Biol. Chem. 267:14879-14883 (1992) | |

| Signature | /lqbal Chowdhury/ (04/01/2009) | Considered | |
|-----------------------|--|--------------------------------|---|
| *EXAMINER: In | nitial if reference considered, whether or not citation is in conformance with MPEP 609. | Draw line through | citation if not in conformance and not considered. Include copy |
| of this form with nex | at communication to applicant 'Applicant's unique citation designation number (option | al) ² See Kinds Cod | es of USPTO Patent Documents at www.uspto.gov.or.MPEP |
| OOL OF Senter Office | on that issued the document, but he two letter code (WIPO Standard ST 3). *For Japane | se patent documents | the indication of the year of the reign of the Emperor must |

The value of the part of the p clock max her if English Ingregar Translation is statisted.

17 Tel. 197 and 198. The information is required by 27 CFR 197 and 198. The information is required to obtain or retain a basefit by the public which is to file (and by the USFTO to process) an explosions. Confidentially is governed by 35 U.S.C. 123 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including public representations of the collection of the collection is estimated to take 2 hours to complete, deading gathering, preparing, and substituting the complete public results and the formation of files. (17 Section 4.15) and the collection is estimated to take 2 hours to complete, because the collection of the colle

PTO/SB/08 (11-07) Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | Complete if Known | | |
|------------------------|-----------------------------------|----------------------|-------------------------|------------------------|------------------|--|
| Substitute f | or form 144 | 9/PTO | | Application Number | 10/537,756 | |
| INFORMATION DISCLOSURE | | | | Filing Date | October 25, 2005 | |
| STATEMENT BY APPLICANT | | First Named Inventor | David John Haydon | | | |
| (Use a | (Use as many sheets as necessary) | | Art Unit | 1652 | | |
| () | | Examiner Name | Iqbal Hossain Chowdhury | | | |
| Sheet 2 Of 4 | | | | Attorney Docket Number | 35813-709.831 | |

| | | NON PATENT LITERATURE DOCUMENTS | |
|-----------------------|--------------|---|----------------|
| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| /IC/ | 19. | Chen et al., "Purification and Properties of Yeast ATP (CTP):tRNA Necleotidyltransferase from Wild Type and Overproducing Cells," J. Biol. Chem. 265:16221-16224 (1990) | |
| /IC/ | 20. | Cho et al., "Use of nucleotide analogs by class I and class II CCA-adding enzymes ((RNA nucleotidyltranserase): Deciphering the basis for nucleotide selection," RNA 9:970-981 (2003) | |
| /IC/ | 21. | De Backer et al, "Genomic profiling of the response of Candida albicans to irraconazole treatment using a DNA microarray," Antimicrobial Agents + Chemother. 45(6):1660-1670 (2001) | |
| /IC/ | 22. | De Backer et al., "Recent developments in molecular genetics of Candida albicans," Ann. Rev. Microbiology 54:463-498 (2000) | |
| /IC/ | 23. | De Backer et al., "An antisense-based functional genomics approach for identification of genes critical for growth of Candida albicans," Nature Biotech. 19(3):235-241 (2001) | |
| /IC/ | 24. | De Backer et al., "RNA-mediated gene silencing in non-pathogenic and pathogenic fungi," Curr. Op. Microbiol. 5(3):323-329 (2002) | |
| /IC/ | 25. | Deng et al., "Isolation and nucleotide sequence of a gene encoding tRNA nucleotidyltransferase from Kluyveromyces lactis," Yeast 16:945-952 (2000) | |
| /IC/ | 26. | Ghannoum et al., "Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance," Clin. Microbiol. Rev. 12(4):501-517 (1999) | |
| /IC/ | 27. | Glaever et al., "Functional profiling of the Saccharomyces cerevisiae genome," Nature 418(6896): 387-391 (2002) | |
| /IC/ | 28. | Hanic-Joyce, et al., "Characterization of a gene encoding tRNA nucleotidyltransferase | |

| | Date Considered |
|--|--------------------|
|--|--------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw is the through citation if not in conformance and not considered include copy of this form with most communication to applicant. Applicant's unique citation designation number (optional) "Sex Kinds Codes or USPTO Parter Documents at www uping yor well'yor." Sex Kinds Codes or USPTO Parter Documents at which was presented in the conformation of the parter Documents at which was presented in the parter Documents at which the parter Documents at which was presented in the parter Documents at which was presented in the parter Documents at which was presented in the parter Documents at which the parter Documents at which was presented in the parter Documents at which the parter Docum

check must here it lengths language [Institution in attitudes] and LISA. The information is required to define or retain a beautify to be public which is no file (and by the USETTO to process) have included in a continuous an executive by 10 CM or 10 and 10 CM. The information is required to define or retain a beautify to the public which is no file (and by the USETTO to process) and an extended to the 10 CM or 10

PTO/SB/08 (11-07) Approved for use through 11/30/2007. OMB 0651-0031

| | | | | Complete if Known | | |
|------------------------|-----------------------------------|----------------------|-------------------------|------------------------|------------------|--|
| Substitute f | or form 144 | 9/PTO | | Application Number | 10/537,756 | |
| INFORMATION DISCLOSURE | | | | Filing Date | October 25, 2005 | |
| STATEMENT BY APPLICANT | | First Named Inventor | David John Haydon | | | |
| (Use a | (Use as many sheets as necessary) | | Art Unit | 1652 | | |
| (, | | Examiner Name | Iqbal Hossain Chowdhury | | | |
| Sheet | 3 | Of | 4 | Attorney Docket Number | 35813-709.831 | |

| | | NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the | _ |
|-----------------------|--------------|--|---|
| Examiner Initials* | Cite No.1 | item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Т |
| | | from Candida glabrata," Yeast 19(16):1399-1411 (2002) | |
| /IC/ | 29. | Invitrogen Product Catalog 2000:pp.viii and 79 | |
| /IC/ | 30. | Kroger et al., "Reversible Inactivation of IRNA Nucleotidyltransferase from Baker's Yeast by IRNA ^{ne} Containing Iodoacetamide-Alkylated 2-Thiocytidine in Normal and Additional Positions," Eur. J. Biochem. 95:341-348(1970) | |
| /IC/ | 31. | Navarro et al., "Characteristics of the Inhibition and Metabolic Inactivation of the Yeast tRNA Nucelotidyltransferase," Italian J. Biochem. 40:295-303 (1991) | |
| /IC/ | 32. | Onishi et al., "Discovery of Novel Antifungal (1,3)-β-D-Glucan Synthase Inhibitors," Antimicrobial Agents and Chemotherapy 44(2):368-377 (2000) | |
| /IC/ | 33. | Peltz et al., "A Mutation in the tRNA Nucleotidyltransferase Gene Promotes Stabilization of mRNAs in Saccharomyces cerevisiae," Mol. Cell Biol. 12:5778-5784 (1992) | |
| /IC/ | 34. | Roemer et al., "Large-scale essential gene identification in Candida albicans and application to antifungal drug discovery," Mol. Microbiol. 50(1):167-181 (2003) | |
| /IC/ | 35. | Song et al, "RAM2: an essential gene in the prenylation pathway of Candida albicans," Microbiol. 149:219-259 (2003) | |
| /IC/ | 36. | Spaltmann et al., "Computer-aided target selection-prioritizing targets for antifungal drug discovery," Drug Discovery Today, 4: 17-26 (1999) | |
| /IC/ | 37. | Sternbach et al., "Afinity Labelling of tRNA Nucleotidyltransferase from Baker's Yeast with tRNA Phe Modified on the 3'-Terminus," Eur. J. Biochem. 67:215-221 (1976) | |
| /IC/ | 38. | Vesses et al., "ABGI, a Novel and Essential Candida albicans Gene Encoding a Vauolar Protein Involved in Cytokinesis and Hyphal Branching," Eukaryotic Cell 4(6):1088-1101 (2005) | |

L SQUARMS. That all reference considered, whether or not existing in a conformance with MEP (FO). Down user-completation first in conformance and not considered. Include copy of the conformance considered with the conformance of the conforma

coccs mex. here it ranges integrages pressures as statistical.

This collection of information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentially is governed by \$3 U.S. C. 12 and \$7 CFR 114 This collection is estimated to take 2 hours to complete, including purposering, and submitting the results of the collection is estimated to take 2 hours to complete, including purposering, and submitting the retaining the results of the collection of the coll

PTO/SB/08 (11-07) Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

| | | | | Complete if Known | | |
|------------------------------|-----------------------------------|--|---------------|-------------------------|------------------|--|
| Substitute for form 1449/PTO | | | | Application Number | 10/537,756 | |
| INFORM | MATION | DISC | LOSURE | Filing Date | October 25, 2005 | |
| STATEMENT BY APPLICANT | | First Named Inventor David John Haydon | | | | |
| (Use a | (Use as many sheets as necessary) | | Art Unit | 1652 | | |
| | | | Examiner Name | Iqbal Hossain Chowdhury | | |
| Sheet 4 Of 4 | | | 4 | Attorney Docket Number | 35813-709.831 | |

| Examiner Initials* | Cite No.1 | Include name of the author (in CAPITAL LETTERS), tide of the article (when appropriate), tide of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T' |
|-----------------------|--------------|---|----|
| /IC/ | 39. | Weiner, Alan, "tRNA Maturation: RNA Polymerization without a Nucleic Acid Template," Curr. Biol. 14:R883-R885 (2004) | |
| /IC/ | 40. | Wolfe et al., "Mechanisms Leading to and the Consequences of Altering the Normal Distribution of ATP(CTP):tRNA Nucelotidyltransferase in Yeast," J. Biol. Chem. 271:4679-4686 (1996) | |
| /IC/ | 41. | Wood et al., "The genome sequence of Schizosaccharomyces pombe," Nature 415(6874): 871-880 (2002) | |
| /IC/ | 42. | Yue et al., "The CCA-adding Enzyme Has a Single Active Site," J. Biol. Chem. 273:29693-29700 (1998) | |

| Examiner | /labal Chowdhury/ (04/01/2009) | Date | |
|-----------|--------------------------------|------------|--|
| Signature | /iqoai Cnowdnury/ (04/01/2009) | Considered | |
| | | | |

^{**}EXAMINER: Initial if reference considered, whether or not classifies in constrained with MTEP 600°). The line through classes from its conformance and considered in the conformance and considered in the conformance and one considered in the conformance and considered in the conformance and conforman

ORCE TEXT OF It Engines magging interactions interaction and 1.98. The information is required to obtain or retain a beautiful type paths, which is to Effect (and by the USFTO to preced) and the preceding of the preceding of the preceding of the preceding pathways, preceding pathways,